Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Bm_squib
MOTIVAL TABLETS SCHEDULING STATUS: S5 PROPRIETARY NAME (and dosage form): MOTIVAL TABLETS COMPOSITION MOTIVAL tablets each contain 0,5 mg fluphenazine hydrochloride and 10 mg nortriptyline base as the hydrochloride. PHARMACOLOGICAL CLASSIFICATION Category A 2.6 Tranquillizers. PHARMACOLOGICAL ACTION MOTIVAL contains fluphenazine, a trifluoromethyl phenothiazine derivative, intended for the management of anxiety and tension states and nortriptyline, a tricyclic antidepressant intended for the treatment of mental depression. Pharmacokinetics: The pharmacokinetics and dose-response of both nortriptyline and fluphenazine are characterized by inter-individual variability. After oral administration, both nortriptyline and fluphenazine are well absorbed from the gastrointestinal tract and extensively metabolized during "first pass" metabolism in the liver. Both agents are widely distributed in the brain and other organs and are highly bound to plasma proteins. The plasma half-life of nortriptyline ranges from approximately 18 to 93 hours. The serum half-life of fluphenazine HCl is approximately 15 hours. INDICATIONS Treatment of patients with mild to moderate mixed anxiety depression states. CONTRA-INDICATIONS MOTIVAL is contraindicated: • in patients with a history of hypersensitivity to fluphenazine, nortriptyline or any other phenothiazine or dibenzazapine. • during the acute recovery period after myocardial infarction, cardiac failure and ischaemic heart disease. • in patients with suspected or established brain damage. • in patients receiving large doses of central nervous system depressants (alcohol, barbiturates, narcotics, hypnotics, ets.) • in comatose or severely depressed states. • in patients with blood dyscrasia or liver damage • during pregnancy and lactation • in patients with g Read the complete document